Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Key Ingredients to Getting a Drug Combination Approved: Insights from Dr. Marjorie Green at ESMO TAT 2025

    At ESMO TAT 2025, Dr. Marjorie Green, Senior Vice President and Head of Oncology at Merck, delivered a compelling presentation titled “Key Ingredients to Getting a Drug Combination Approved: Industry…

    2025.04.16
  • EBMT 2025 | Prof. Qingxiao Song: Breakthroughs in Steroid-Refractory GI-aGVHD and cGVHD

    Prof. Qingxiao Song: At EBMT 2025, Professor Robert Zeiser from the University of Freiburg presented results from the STARGAZE trial—a multicenter, prospective Phase II study that, for the first time,…

    2025.04.16
  • EBMT 2025 | Prof. Yue Lu: CR and MRD Illuminate Prognosis in KMT2A-Rearranged Acute Leukemia

    With the spring breeze of April sweeping through Florence, the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was successfully held from March 30…

    2025.04.16
  • EBMT 2025 | Prof. Yang Cao: Uncovering the Prognostic Impact of KRAS Mutations in KMT2A-Rearranged AML and Exploring Therapeutic Strategies

    Prof. Yang Cao: KMT2A-rearranged acute myeloid leukemia (KMT2A-r AML), formerly known as MLL-rearranged AML, accounts for approximately 3% to 7% of newly diagnosed AML cases and represents a biologically and…

    2025.04.16
  • EBMT 2025 | Prof. Jun Ma: Spotlight on Cell and Gene Therapy as China’s Innovations Shine on the Global Stage

    Hematology Frontier: Prof. Ma, welcome back to the EBMT Annual Meeting. What are your impressions this year? Are there any highlights that Chinese experts should pay particular attention to? Prof.…

    2025.04.16
  • EBMT 2025 | Prof. Jia Wei: Exploring Synergistic Mechanisms and Sequential Strategies in CAR-T Cell Therapy

    Hematology Frontier: At this year’s EBMT Congress, your team presented three studies related to CAR-T therapy (A093, A134, A082). Among them, Study A093 showed that combining ASCT significantly improves long-term…

    2025.04.16
  • APASL Keynote Address | Academician Jiahong Dong: The Era of Precision Liver Surgery Powered by Smart Technology Has Arrived

    Editor’s Note: On the morning of March 28, the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025) officially opened. During the keynote session, APASL 2025 Scientific Committee Chair, Academician Jiahong Dong of Beijing Tsinghua Changgung Hospital, delivered a keynote speech titled “Precision Surgical Treatment of Liver Diseases”…

    2025.04.16
  • EBMT 2025 | Prof. Fang Liu: From Predictive Models to Rare Disease Cures—Advancing Pediatric Cord Blood Transplantation

    At the 2025 EBMT Annual Meeting, cord blood transplantation (UCBT) emerged as a transformative strategy in the treatment of pediatric hematologic malignancies. Hematopoietic stem cell transplantation (HSCT) remains a life-saving therapy, and UCBT is gaining attention for its unique clinical advantages. During the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation…

    2025.04.16
«previous next»
Recent Posts
  • Prof. Chunrui Li: The Leap from Target Innovation to Clinical Breakthroughs in CAR-T Therapy for Multiple Myeloma
  • Professor He Huang: Uniting Global Strength to Lead the Frontier丨2025 International Cell and Immunotherapy Congress
  • ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy 
  • Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?
  • Precision Targeted Therapy for Bladder Cancer Reaches a New Milestone: Professor Xu Tao’s Team from Peking University People’s Hospital Demonstrates Potent Synergistic Effects Through Combination Treatment 
Recent Comments
    Archives
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top